Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients by Papaioannou, Alexandra et al.
BioMed  Central
Page 1 of 8
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Longitudinal analysis of vertebral fracture and BMD in a Canadian 
cohort of adult cystic fibrosis patients
Alexandra Papaioannou*1, Courtney C Kennedy1, Andreas Freitag1,2, 
John O'Neill3, Margaret Pui4, George Ioannidis1, Colin Webber5, 
Anjali Pathak1, Suzanne Hansen2, Rosamund Hennessey2 and 
Jonathan D Adachi1,3
Address: 1Department of Medicine, McMaster University, 1200 Main St W., Hamilton ON, L8N 3Z5, Canada , 2Hamilton Health Sciences, 
McMaster University Site, 1200 Main St W., Hamilton, ON, L8N 3Z5, Canada, 3St. Joseph's Healthcare/McMaster University, 1200 Main St W., 
Hamilton ON, L8N 3Z5, Canada , 4Department of Diagnostic Imaging, Scarborough Hospital, General Division, 3050 Lawrence Avenue E., 
Scarborough, ON, M1P 2V5, Canada  and 5Department of Nuclear Medicine, McMaster University, 1200 Main St W., Hamilton ON, L8N 3Z5, 
Canada
Email: Alexandra Papaioannou* - papaioannou@hhsc.ca; Courtney C Kennedy - kennedyc@hhsc.ca; Andreas Freitag - freitagan@hhsc.ca; 
John O'Neill - joneill2@cogeco.ca; Margaret Pui - radserve@gmail.com; George Ioannidis - g.ioannidis@sympatico.ca; 
Colin Webber - webber@hhsc.ca; Anjali Pathak - anjali_pathak@hotmail.com; Suzanne Hansen - shansen@hhsc.ca; 
Rosamund Hennessey - hennesr@mcmaster.ca; Jonathan D Adachi - jd.adachi@sympatico.ca
* Corresponding author    
Abstract
Background: Vertebral fractures in patients with cystic fibrosis (CF) may contribute to an accelerated
decline in lung function and can be a contraindication to lung transplantation. In this study, we examined
longitudinal change in bone mineral density (BMD) and the prevalence of vertebral fractures in adult CF
patients, without lung-transplant, attending a Canadian specialty clinic.
Methods: Retrospective chart review of all patients attending an Adult Cystic Fibrosis Clinic at Hamilton
Health Sciences in Hamilton, Canada. Forty-nine of 56 adults met inclusion criteria. Chest radiographs
were graded by consensus approach using Genant's semi-quantitative method to identify and grade
fractured vertebrae. Dual x-ray absorptiometry (DXA) scans were also reviewed.
Results: The mean age of the cohort was 25.2 years (SD 9.4), 43% were male. The mean body mass index
(BMI) was 19.8 (2.8) for males and 21.7 (5.1) for females. At baseline, the rate of at least one vertebral
fracture was 16.3%; rising to 21.3% (prevalent and incident) after a 3-year follow-up. The mean BMD T-or
Z-scores at baseline were -0.80 (SD 1.1) at the lumbar spine, -0.57 (SD 0.97) at the proximal femur, and
-0.71 (SD 1.1) at the whole body. Over approximately 4-years, the mean percent change in BMD was -
1.93% at the proximal femur and -0.73% at the lumbar spine.
Conclusion:  Approximately one in five CF patients demonstrated at least one or more vertebral
fractures. Moderate declines in BMD were observed. Given the high rate of vertebral fractures noted in
this cohort of adult CF patients, and the negative impact they have on compromised lung functioning,
regular screening for vertebral fractures should be considered on routine chest radiographs.
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Background
Cystic Fibrosis (CF) is among the most common fatal
autosomal recessive genetic diseases in the Caucasian
population. Since those born with CF are now living sig-
nificantly longer, there is a definite need to address a
range of erging comorbid conditions, which were not pre-
viously considered for a CF population. Low bone min-
eral density (BMD) is common in adult CF patients and
has been termed CF-related bone disease [1,2]. The under-
lying etiology of low BMD is likely multi-factorial [1-4],
however several reports support the hypothesis that the
inflammatory response to chronic pulmonary infection
plays a significant role in bone loss [1,3,5].
In non-CF populations, vertebral fractures are the most
common type of osteoporotic fracture [6] and have
important consequences, including increased risk for sub-
sequent fracture [7-11], increased mortality [8,12-15],
and reduced quality of life [16-19]. In a CF population, a
further consequence of a vertebral (thoracic) fracture is an
accelerated decline in lung function (i.e. structural altera-
tion of the chest wall) and contraindication to lung trans-
plantation, an important treatment option for CF patients
[1,2]. As CF patients often have routine chest radiographs,
screening for vertebral fracture may be an important con-
sideration in this population.
The pathophysiology of CF-related bone disease is not
well understood and there are few longitudinal reports on
BMD and vertebral fracture. Previous studies in this area
have examined CF patients cross-sectionally or only over
a short term. Two recent cross-sectional studies found a
high rate of vertebral fracture in general CF populations
[20,21].
In our Canadian cohort, the purpose of this study was to
examine: 1) longitudinal changes in BMD and 2) the rate
of vertebral fractures in adults with CF, who have moder-
ate to severe respiratory impairment and who have not
undergone lung-transplant.
Methods
Study population
All patients who attended the Adult Cystic Fibrosis Clinic
at Hamilton Health Sciences, McMaster University Medi-
cal Centre (Hamilton, Canada) during 2002 were consid-
ered for this study. To be included, patients must have had
at least one chest radiograph or DXA scan in previous
years (completed as part of routine care in the CF clinic).
Patients who were accepted on a lung-transplant list or
had received a prior organ transplant were excluded. CF
was confirmed by a positive sweat test and deoxyribonu-
cleic acid (DNA) analysis. Of 56 individuals attending the
clinic during 2002, four were excluded due to the unavail-
ability of radiographic results, and three patients were
excluded due to a past lung transplant. The final cohort
consisted of 49 patients. The Institutional Review Board at
McMaster University approved the study.
Radiology review
The first and last available routine chest radiographs (sep-
arated by at least one year) taken between May 1996 and
December 2003 were selected for each participant. Two
board certified radiologists (authors MP and JO) inde-
pendently reviewed chest radiographs (lateral and ante-
rior posterior views) using a modified Genant's semi-
quantitative method [22,23]. This method distinguishes
fractured vertebrae (grades 1, 2 and 3) from non-fractured
vertebrae (grades 0 for no fracture, 0.5 for reduction of
height of less than 20% or reduction in area of less than
10%). A deformity graded 1 and higher (excluding con-
genital or degenerative causes) indicates a reduction in
vertebral height (anterior, posterior, or middle) of greater
than or equal to 20–25%. Grade 1 is considered a mild
fracture, Grade 2 a moderate fracture, and Grade 3 a severe
fracture. Differences of scores between radiologists were
resolved by consensus.
Bone densitometry
A medical physicist (author CW) reviewed all annual DXA
scans of the lumbar spine, proximal femur (total region),
and whole body taken during the study period. All DXA
scans were performed on a Hologic QDR 4500A densito-
meter (Hologic Inc., Bedford, MA, USA). BMD measure-
ments were reported in g/cm2, and T- or Z-scores.
Expression of an adult BMD as a T-score incorporates the
typical BMD loss from peak bone mass that is associated
with aging as well as any BMD loss relative to an age-
matched peer. By definition, a T-score is not applicable to
children. Consequently for subjects aged 19 years or less,
BMD values were expressed as Z-scores.
Clinical/laboratory variables
Research assistants abstracted clinical and demographic
data from clinic charts for the nearest clinic visit within 9-
months of both the baseline radiograph and DXA scan
(i.e. if taken at non-coincident time periods). Data
abstracted included height, weight; use of inhaled ster-
oids, bisphosphonates, hormone replacement therapy,
oral contraception, calcium and vitamin D supplements;
laboratory tests and pulmonary functioning including
forced expiratory volume in 1 second (FEV1) and forced
vital capacity (FVC). Dietary calcium intake was not avail-
able. Charts were also reviewed for any evidence of oral
corticosteroid use between the baseline and follow-up
radiograph/DXA examinations and the cumulative
number of milligrams taken was recorded.
Routine laboratory results were downloaded from the
computerized hospital database. Phosphate, alkalineBMC Musculoskeletal Disorders 2008, 9:125 http://www.biomedcentral.com/1471-2474/9/125
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phosphatase, serum calcium, albumin, alanine ami-
notransferase (ALT), g-glutamyltransferase (GGT) and cre-
atinine were measured with automatic analyzers.
Commercially available kits (Nichols Institute Diagnos-
tics, San Clemente, CA, USA) were used to measure par-
athyroid hormone (PTH; Nichols Advantage Bio-Intact
PTH (1–84) immunometric assay) and 25-hydroxyvita-
min D (25-OHD; Nichols Advantage 25-Hydroxyvitamin
D assay).
Statistical analysis
Analyses were performed with SPSS (version 13.0; SPSS
Inc., Chicago, IL, USA) and SAS/STAT (version 8.0; SAS
Institute Inc., Cary, NC, USA) software packages. Clinical
and laboratory variables are summarized as means and
standard deviations, and medication/supplementation
use (yes/no) as proportions. Due to deviations from nor-
mality and the small sample size of the fracture group, dif-
ferences in baseline characteristics (continuous variables)
between fracture versus non-fracture patients were deter-
mined by Mann-Whitney U-test. Fisher's exact test was
used to examine differences between proportions.
For the BMD analysis, all individuals had two to five BMD
measures during the course of the study. To incorporate
all BMD measurements, a regression slope was calculated
using all available measurements for each patient. The
slope represents the average yearly bone mineral density
change over the entire follow-up period for each patient.
This analysis takes into account the differing numbers of
BMD measurements and the length of follow-up for each
patient. Separate analyses were performed for the lumbar
spine, whole body, and proximal femur (average of right
and left sides). Baseline BMD and variables that were sig-
nificant in univariate analysis were included in multi-var-
iable regression models to estimate percent BMD change
per year. In all analyses, a 2-sided p-value of < 0.05 was
considered significant.
Results
Overall, the mean age of the cohort was 25.2 years (SD
9.4), 43% were male. Seventy-five percent of the sample
was between ages 15–31 years; 25% were ages 32–51
years. The median age was 23.0 years. Table 1 displays
baseline patient characteristics for the fracture (prevalent/
baseline) and non-fracture groups. The mean age of frac-
Table 1: Baseline characteristics* for the entire study cohort and by vertebral fracture status
Overall
n = 49
Nonfracture Group
n = 41
Fracture Groupa 
n = 8
p-value
Valid n, Nonfracture/Fracture
Male gender, % 41/8 42.9 39.0 62.5 0.263
Age, years 41/8 25.2 (9.4) 23.8 (8.7) 32.7 (10.3) 0.024†
Weight, kg
males 16/5 59.5 (9.2) 56.1 (7.4) 70.4 (5.3) 0.003†
females 25/3 57.4 (16.4) 57.3 (17.5) 58.0 (11.5) 0.726
Height, cm, 41/8 166.8 (7.9) 166.1 (7.7) 170.3 (8.9) 0.175
BMI, kg/m2
males 16/5 19.8 (2.8) 18.9 (2.2) 22.8 (2.4) 0.004†
females 25/3 21.7 (5.1) 21.7 (5.3) 22.3 (3.7) 0.726
FEV1 39/8 2.2 (0.9) 2.2 (0.9) 2.5 (0.7) 0.202
FVC 39/8 3.1 (0.9) 3.0 (0.9) 3.4 (0.9) 0.098
Hemoglobin g/L 38/7 139.2 (14.8) 138.1 (14.6) 144.9 (15.2) 0.301
Creatinine, umol/L 34/7 66.8 (17.4) 64.8 (18.1) 76.0 (10.0) 0.045†
Calcium, mmol/L 34/5 2.3 (0.1) 2.3 (0.1) 2.3 (0.1) 0.657
Albumin, g/L 37/8 39.7 (3.7) 39.8 (3.9) 39.3 (2.5) 0.550
25-hydroxyvitamin D, nmol/L 26/4 61.9 (28.8) 61.5 (31.0) 64.6 (5.4) 0.617
Parathyroid hormone, pg/ml 17/4 28.0 (17.7) 24.8 (18.0) 41.5 (6.7) 0.120
Phosphate, mmol/L 32/5 1.2 (0.2) 1.2 (0.2) 1.3 (0.1) 0.813
Alkaline Phosphatase, U/L 37/8 121.8 (91.4) 116.6 (89.7) 146.1 (101.5) 0.082
Alanine Aminotransferase, IU/L 36/8 32.5 (29.1) 29.6 (22.0) 45.6 (50.5) 0.560
g-glutamyltransferase, U/L 37/7 31.2 (51.8) 26.7 (39.9) 55.1 (94.2) 0.297
Inhaled Steroids, % yes 41/8 55.1 51.2 75.0 0.269
Vitamin D (ADEK), % yes 41/8 55.1 53.7 62.5a 0.715
Data expressed as mean (SD) or proportion.
*Data was abstracted within 9-months of baseline radiograph.
†p < 0.05
aFractures present at baseline (prevalent fractures)
BMI, body mass index; FEV1, Forced Expiratory Volume in 1 second; FVC, Forced Vital CapacityBMC Musculoskeletal Disorders 2008, 9:125 http://www.biomedcentral.com/1471-2474/9/125
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ture patients was significantly higher than that of non-
fracture patients (32.7 years versus 23.8). Males with ver-
tebral fracture had significantly higher weight and body
mass index (BMI) scores than those without. Several of
the laboratory variables were higher in the fracture than
non-fracture group (Table 1), however we lacked power to
see this statistically. Creatinine was significantly higher in
the fracture group.
At baseline, eight out of 49 patients (16.3%) had at least
one prevalent Grade 1 fracture (Table 2). Multiple verte-
bral fractures were noted in four (8.2%) patients. A sec-
ond radiograph was available for 47/49 patients. Neither
of the two patients without a follow-up radiograph had a
vertebral fracture noted at baseline. The mean follow-up
between each patient's first and last radiograph was 3.3
years (SD 1.4). During this period, four new fractures
occurred (incidence rate of 8.5%); three patients had a
new first fracture, and one patient had an additional ver-
tebral fracture since baseline (Table 2). The mean age at
follow-up for patients with a new fracture was 35.6 years
(SD 14.7) versus 28.1 years (SD 8.8) for patients with no
fracture (not statistically significant but lacked power).
One patient had a fracture at baseline that was not appar-
ent at follow-up (two grade 0.5 fractures were noted
instead of one grade 1 and one grade 0.5 as at baseline).
Thus, at follow-up, the overall rate of at least one Grade 1
vertebral fracture (both incident and prevalent) increased
to 21.3% of patients (10/47; Table 2).
During the study period, 14 of 47 (30%) patients had
taken oral corticosteroids. The mean cumulative dose per
patient was 1517 mg and the mean cumulative number of
days taking oral corticosteroids was 37 (SD 21.3). One of
these patients taking corticosteroids had a new incident
fracture (cumulative corticosteroid dose of 3000 mg over
68 days) and the remainder had no prevalent or incident
fractures. Three patients were taking a bisphosphonate;
none had a prevalent or incident fracture. The rate of
inhaled steroid use and Vitamin D supplementation at
baseline was higher in the fracture group, however we
likely lacked power to see a statistical difference (Table 1).
Only two patients were taking calcium supplementation
at baseline, although patients may have been taking a
multivitamin and dietary calcium levels were monitored
by the clinic nutritionist (results not available).
Bone mineral density
Table 3 presents mean BMD values in g/cm2 and T-or Z-
scores (lumbar spine, proximal femur, and whole body
sites) for all DXA measures during the study period (up to
five for some patients). The mean BMD T-or Z-scores at
baseline were -0.80 (SD 1.1) at the lumbar spine, -0.57
(SD 0.97) at the proximal femur, and -0.71 (SD 1.1) at the
whole body. During the study period, 35 of 49 patients
had at least two DXA scans; for these patients, the mean
BMD percent change/year (adjusted) is presented in Table
4. Over a mean follow-up of 4.03 years (SD 1.45), the
overall rate of bone loss was -0.73% at the lumbar spine,
-1.93% at the proximal femur, and -0.40% at the whole
body. One outlier who had a BMD change of +12%/year
was left out of the lumbar spine analysis (the result was
attributed to growth stage and a significant increase in
BMI).
Although we did not have adequate sample size to make
a meaningful comparison, we examined the longitudinal
BMD change for patients who had a final DXA scan that
was within one year of the follow-up chest radiograph
(over 80% were performed within the same month). At
the whole body, the crude mean percent BMD change
over a mean follow-up of 4.1 years was -3.62% (SD 3.46)
for fracture patients (incident or prevalent; N = 5), and -
1.90% (SD 3.34) for non-fracture patients (N = 22). Cor-
Table 2: Vertebral fractures in the study cohort*
Baseline
n = 49
Follow-up
n = 47†
No. of patients 
with fracture
(at least one)
No. of patients 
without
Total No. 
fractures
No. of patients 
with fracture
(at least one)
No. of patients 
without
Total No. 
fractures
New Vertebral 
Fracture (≥Grade 
1)
--- 4 a 43 4
All Vertebral 
Fractureb (≥Grade 
1)
84 1 1 2 1 0 3 7 c 15
*Mean length of follow-up between baseline and follow-up radiographs was 3.3 years (SD 1.4)
†Of the two patients missing a follow-up radiograph, neither patient had a fracture present at baseline.
aOne patient also had a prevalent fracture at baseline.
bFor follow-up, this includes both prevalent and incident fractures.
cOne patient had a fracture indicated at baseline but not on the follow-up radiograph.BMC Musculoskeletal Disorders 2008, 9:125 http://www.biomedcentral.com/1471-2474/9/125
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respondingly, at the lumber spine it was -3.69% (SD 8.21)
for fracture patients (N = 5) and -1.01% (SD 4.59) for
non-fracture patients (N = 23). At the proximal femur
(average of right and left), it was -6.04 (SD 12.1) for frac-
ture patients (N = 5) and -2.32 (SD 7.68) for non-fracture
patients (N = 23).
Discussion
This study demonstrates that the prevalence of vertebral
fracture in young adults (mean age 25.2, SD 9.4) with CF
and without lung transplantation is similar to Canadian
population-based rates of vertebral fracture in men and
women over age 50 [24]. In the Canadian Multicentre
Osteoporosis Study (CaMos), vertebral fracture rates in
Canadians over age 50 were 21.5% for men and 23.5% for
women. In our CF cohort, the overall rate of at least one
vertebral fracture (prevalent and incident) at follow-up
was 21.3% and multiple fractures occurred in four of
these patients. The incidence of vertebral fractures over a
mean follow-up of 3.3 years was 8.5% (10/47). Consider-
ing that the patients in our study were on average 25 plus
years younger than CaMos participants, and that the
CaMos study uses quantitative morphometry which may
yield a higher estimate than the semi-quantitative
approach (approximately double by one estimate) [25],
the rate of vertebral fractures in adults with CF appears
high.
Patients with vertebral fracture were significantly older
than their non-fracture counterparts (Table 1). Males with
vertebral fractures had a greater BMI than those without
fractures, although the mean BMI of both groups were in
the healthy range.
Previous cross-sectional studies in CF patients with varied
disease severity have found vertebral fracture rates of 17%
to 26% [26,27]. In a cohort of late-stage cystic fibrosis
patients referred for lung transplantation, a review of
chest radiographs revealed that 51% of patients had one
or more unreported vertebral compression fractures
(>20% anterior wedging), and 15% of patients had unre-
ported rib fractures [28,29].
Two recent cross-sectional studies of CF cohorts similar to
our study (i.e. general, non-transplant), have also exam-
ined vertebral fractures in relation to BMD. A Canadian
study [21] and Italian study [20] found a 7% and 27% ver-
tebral fracture rate, respectively. In the former study, cross-
sectional BMD was not related to fracture prevalence, and
in the latter, cross-sectional BMD was actually higher in
the fracture group. Although we were not able to ade-
quately examine this issue due to small sample size, our
data suggests that during the study period the crude rate of
BMD  loss  was greater in the fracture than non-fracture
group. Whether BMD loss (versus cross-sectional BMD) is
predictive of fracture should be evaluated in a future lon-
gitudinal study.
In the general population, once peak bone mass has been
reached, the rate of bone loss tends to be somewhat stable
Table 3: Bone mineral density (BMD) over study period*, mean (SD)
BMD 1
(Baseline)
BMD 2 BMD 3 BMD 4 BMD 5
Lumbar Spine, n n = 45 n = 36 n = 28 n = 17 n = 10
T-score/Z-score† (SD) -0.80 (1.10) -0.91 (1.09) -0.95 (0.94) -1.08 (1.01) -1.17 (1.26)
BMD, g/cm2 (SD) 0.972 (0.12) 0.968 (0.12) 0.968 (0.11) 0.956 (0.11) 0.944 (1.14)
Proximal Femura, n n = 41 n = 37 n = 29 n = 18 n = 10
T-score/Z-score† (SD) -0.57 (0.97) -0.59 (1.02) -0.71 (0.88) -0.82 (0.89) -0.92 (1.14)
BMD, g/cm2 (SD) 0.902 (0.13) 0.898 (0.14) 0.888 (0.12) 0.869 (0.12) 0.857 (0.16)
Whole Body, n n = 46 n = 36 n = 27 n = 18 n = 10
T-score/Z-score† (SD) -0.71 (1.11) -0.50 (1.07) -0.61 (1.13) -0.65 (1.04) -0.72 (1.25)
BMD, g/cm2 (SD) 1.120 (0.97) 1.136 (0.11) 1.123 (0.11) 1.111 (0.10) 1.100 (0.11)
* The mean follow-up time between first and last BMD examination was 4.03 years (SD 1.45)
†T-scores for participants over 19 years of age, and Z-scores for those under 19 years of age.
aAverage of left and right sides
Table 4: Multivariable-adjusted percent BMD change/year, mean 
(SD)
% BMD change/year (adjusted)
Lumbar Spine -0.18a (1.59)*
n = 30
Proximal Femur† -0.48b (1.39)
n = 28
Whole Body -0.10c (1.07)
n = 35
All available DXA scans per individual were used in calculating the 
slope of percent BMD change.
*Outlier removed
† Average of left and right sides
aAdjusted for baseline BMD; alkaline phosphatase and serum calcium 
laboratory levels
bAdjusted for Forced Expiratory Volume, serum calcium, and dosage 
of oral steroids
cAdjusted for years of follow-up and ageBMC Musculoskeletal Disorders 2008, 9:125 http://www.biomedcentral.com/1471-2474/9/125
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with age until the fifth and sixth decades [30]. In our
cohort of young adults, we found moderate declines (i.e.
-0.73, -1.93, -0.40 percent BMD change, adjusted) in bone
loss at the lumbar spine, proximal hip, and whole body in
both fracture and non-fracture patients over 4-years of fol-
low-up. Our results exhibit a similar trend to Haworth et
al. [31] who examined percent change in BMD over a 1-
year follow-up. In that study, annual bone loss occurred
particularly for adults >25 years (N = 57), where a decline
of -1.9% and -1.5% occurred at the femoral neck and total
hip (no loss was observed at the lumbar spine).
Bone quality as opposed to simply quantity or mass, and
its relationship to fractures, requires further examination
in CF patients. Increasingly, an emphasis on bone quality
is emerging in osteoporosis research [32], and this may
prove to be a particularly relevant topic to CF patients.
BMD as measured by DXA may not adequately predict
fracture risk in CF patients [20,21]. Quantitative ultra-
sound (QUS) is another alternative that provides infor-
mation on the structural organization of bone in addition
to bone mass. QUS may be particularly applicable for
patients with reduced bone quality such as patients with
corticosteroid induced osteoporosis [33]. In a population-
based, epidemiological study (men and women age 42–
82 years), QUS of the calcaneum has also been shown to
predict fracture risk [34].
Recently, Rossini et al. [35] examined whether QUS could
discriminate between adult CF patients with and without
vertebral fractures. In the cohort of 172 CF patients, mean
age of 27 years, 44% were previously or currently taking
oral corticosteroids. Approximately 1 in 3 patients had a
vertebral deformity. Overall, only phalangeal QUS as
opposed to calcaneal QUS or DXA measures were able to
discriminate between patients with and without vertebral
fractures. Thus, the hypothesis that CF patients have qual-
itative alterations in bone, which may be independent of
BMD, appears warranted and requires further study.
Our study is limited by a number of factors. We relied on
retrospective clinic data extending over a number of years.
DXA scans and chest radiographs were considered coinci-
dent provided they were performed within one year of
each other (however over 80% were within 1-month). The
ages of the subjects in our study ranged from 15 to 51
years, with a median age of 23. Thus, both young and
middle-aged adults were included, whose clinical and
bone-related characteristics may differ.
One patient in our study had a grade 1 fracture indicated
at baseline but not on the follow-up radiograph (instead
it was graded 0.5). This is a potential problem of Genant's
semi-quantitative method used in this study [22,23].
Although this method is probably the most widely cited in
osteoporosis studies, it depends on the recognition of the
radiological signs of fracture by experienced observers
[25]. There is considerable debate regarding the level of
deformity and accuracy of reporting, particularly that with
Genant's method the separation of the grades is not
explicit [25]. Grade 1 is considered a fracture as per
Genant's method; grade 0. 5 is an observable deformity
but represents a reduction in height or area less than the
criterion for fracture.
Conclusion
Recent studies have examined bisphosphonates for the
treatment of low bone mass in CF patients, demonstrating
a substantial improvement in BMD after one year [36,37].
Future studies should examine whether bisphosphonate
or other treatment in CF patients also produces a conse-
quent reduction in vertebral (and non-vertebral) frac-
tures. Given the high rate of vertebral fractures noted in CF
patients, and the potential negative impact they have on
compromised lung functioning, regular screening for ver-
tebral fractures should be considered on routine chest
radiographs.
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